- Home
- IVVD vs ARQQ Comparison
IVVD vs ARQQ Comparison
Compare IVVD & ARQQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IVVD | ARQQ |
|---|---|---|
| Founded | 2020 | 2017 |
| Country | United States | United Kingdom |
| Employees | N/A | 91 |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 201.9M | 211.3M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | IVVD | ARQQ |
|---|---|---|
| Price | $0.61 | $18.00 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | $8.75 | ★ $60.00 |
| AVG Volume (30 Days) | ★ 5.2M | 1.4M |
| Earning Date | 05-08-2026 | 05-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 79.02 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $53,426,000.00 | N/A |
| Revenue This Year | $61.57 | $381.13 |
| Revenue Next Year | $41.42 | $212.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 110.47 | N/A |
| 52 Week Low | $0.49 | $11.52 |
| 52 Week High | $3.07 | $62.00 |
Technical Indicators
Market Signals| Indicator | IVVD | ARQQ |
|---|---|---|
| Relative Strength Index (RSI) | 28.31 | 44.97 |
| Support Level | N/A | $12.04 |
| Resistance Level | $1.01 | $30.46 |
| Average True Range (ATR) | 0.08 | 2.18 |
| MACD | -0.01 | -0.73 |
| Stochastic Oscillator | 1.97 | 14.04 |
Price Performance
Historical ComparisonAbout IVVD Invivyd Inc.
Invivyd Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of monoclonal antibody (mAb) therapies for the prevention and treatment of serious viral infectious diseases. Its lead product, PEMGARDA (pemivibart), received emergency use authorization from the U.S. FDA for the pre-exposure prevention of COVID-19 in certain immunocompromised individuals. The company is also developing next-generation antibody candidates, including VYD2311 for COVID-19 and VBY329 for RSV infections, while continuing research on additional antibodies targeting other viral diseases such as measles.
About ARQQ Arqit Quantum Inc.
Arqit Quantum Inc is a cybersecurity company that has pioneered a symmetric key agreement technology that makes the communications links of any networked device or data at rest secure against current and future forms of cyber attack - even an attack from a quantum computer. The company delivers its symmetric key agreement technology via its product SKA-Platform. The firm operates in one segment, that is, the provision of cybersecurity services. The company operates and generates its revenue from UK.